tradingkey.logo
tradingkey.logo
Search

Evolus Inc

EOLS
Add to Watchlist
6.900USD
+0.160+2.37%
Close 07/02, 13:00ETQuotes delayed by 15 min
454.29MMarket Cap
LossP/E TTM

More Details of Evolus Inc Company

Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.

Evolus Inc Info

Ticker SymbolEOLS
Company nameEvolus Inc
IPO dateFeb 08, 2018
CEOMoatazedi (David)
Number of employees332
Security typeOrdinary Share
Fiscal year-endFeb 08
Address520 Newport Center Dr Ste 1200
CityNEWPORT BEACH
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92660-7022
Phone19492844555
Websitehttps://www.evolus.com/
Ticker SymbolEOLS
IPO dateFeb 08, 2018
CEOMoatazedi (David)

Company Executives of Evolus Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Vikram Malik
Mr. Vikram Malik
Independent Chairman of the Board
Independent Chairman of the Board
243.01K
-28.17%
Ms. Tatjana Mitchell
Ms. Tatjana Mitchell
Chief Financial Officer
Chief Financial Officer
226.09K
+53.73%
Mr. David Moatazedi
Mr. David Moatazedi
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
105.11K
-128.12%
Mrs. Brady Stewart
Mrs. Brady Stewart
Independent Director
Independent Director
88.63K
-43.10%
Mr. David N. Gill
Mr. David N. Gill
Independent Director
Independent Director
41.33K
-92.42%
Dr. Rui L. Avelar, M.D.
Dr. Rui L. Avelar, M.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
--
--
Ms. Karah Parschauer, J.D.
Ms. Karah Parschauer, J.D.
Independent Director
Independent Director
--
--
Mr. Nareg Sagherian
Mr. Nareg Sagherian
Investor Relations
Investor Relations
--
--
Mr. Albert G. White, III
Mr. Albert G. White, III
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Vikram Malik
Mr. Vikram Malik
Independent Chairman of the Board
Independent Chairman of the Board
243.01K
-28.17%
Ms. Tatjana Mitchell
Ms. Tatjana Mitchell
Chief Financial Officer
Chief Financial Officer
226.09K
+53.73%
Mr. David Moatazedi
Mr. David Moatazedi
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
105.11K
-128.12%
Mrs. Brady Stewart
Mrs. Brady Stewart
Independent Director
Independent Director
88.63K
-43.10%
Mr. David N. Gill
Mr. David N. Gill
Independent Director
Independent Director
41.33K
-92.42%
Dr. Rui L. Avelar, M.D.
Dr. Rui L. Avelar, M.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
--
--

FAQs

Who are the top five shareholders of Evolus Inc?

The top five shareholders of Evolus Inc are: Mr. Vikram Malik

How many institutions hold shares of Evolus Inc (EOLS)?

As of 2026Q1, 391 institutions hold shares of Evolus Inc, with a combined market value of approximately 50.03M, accounting for 75.98% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -16021350.00.